The Business Model (How They Make Money)

Eli Lilly and Company is essentially a company that discovers, develops, makes, and sells medicines. Think of them as a medical innovation factory. They make their money by finding new ways to treat diseases, getting those treatments approved by health authorities, and then selling them to hospitals, doctors, and pharmacies around the world. Their core economic engine is driven by their ability to bring innovative, often life-changing, drugs to market.

Their primary revenue streams come from selling their patented pharmaceutical products across several key therapeutic areas. For example, in 2023, their total revenue was $34.1 billion. A significant portion of this revenue comes from:

• Diabetes: Products like Mounjaro, Trulicity, and Humalog contributed substantially. Mounjaro, specifically, brought in $5.3 billion in 2023.
• Oncology (Cancer): Drugs such as Verzenio for breast cancer are key contributors, generating $3.9 billion in 2023.
• Immunology: Taltz for autoimmune diseases is another important product, with $2.5 billion in revenue for 2023.
• Neuroscience: Donanemab, a treatment for early Alzheimer's disease, represents a significant future opportunity.
• Obesity: Zepbound, a newly launched medication for chronic weight management, is quickly becoming a major growth driver, generating $1.1 billion in 2023.

They invest heavily in research and development to find the next big breakthrough medicine, which is crucial because drugs eventually lose their patent protection, allowing cheaper generic versions to enter the market.

The Metrics That Matter Most

For a company like Eli Lilly, which relies on innovation and selling specialized medicines, here are the most important numbers to watch:

1. Revenue: This is the total amount of money Eli Lilly brings in from selling its medicines before any expenses are taken out. For Eli Lilly, revenue is critical because it directly shows how well their products are being adopted and how much demand there is for their drugs. Growing revenue indicates that their new medicines are successful and replacing older ones that might be losing patent protection. In 2023, Eli Lilly's revenue was $34.1 billion.

2. R&D Expenses (Research & Development Expenses): This number tells you how much money Eli Lilly is spending to discover and develop new medicines. For a pharmaceutical company, R&D is like fuel for their future growth. A healthy and consistent investment in R&D, which was $8.3 billion in 2023, shows they are committed to finding the next big drug that will drive their sales years down the road. If R&D spending drops significantly without a clear reason, it could signal fewer new drugs in the pipeline.

3. Net Income: This is Eli Lilly's profit after all expenses, including taxes, have been paid. It's the "bottom line" and tells you how much money the company actually gets to keep from its sales. For Eli Lilly, a strong net income (which was $5.2 billion in 2023) indicates that they are not only selling a lot of drugs but also managing their costs effectively, leading to real profitability.

4. Free Cash Flow: This metric shows the cash Eli Lilly has left over after paying for its day-to-day operations and necessary investments in things like new factories or equipment (CapEx). It's a very pure measure of financial health. For Eli Lilly, robust free cash flow, which was $8.3 billion in 2023, means they have plenty of cash to do things like pay dividends to shareholders, buy back their own stock, or invest in even more R&D without having to borrow money.

How to Value This Company

For a consistently profitable company like Eli Lilly, the most relevant valuation metric is the P/E Ratio (Price-to-Earnings Ratio).

The P/E ratio is a simple way to figure out if a stock is cheap or expensive compared to how much profit the company makes. It tells you how much investors are willing to pay for each dollar of the company's annual earnings.

Here's how it works simply: You take the current price of one share of Eli Lilly's stock and divide it by the profit Eli Lilly made per share (its "earnings per share") over the last year.

• If Eli Lilly's P/E ratio is, for example, 30, it means investors are paying $30 for every $1 of profit the company earned in the past year.
• Why is this good for Eli Lilly? Because Eli Lilly is known for developing innovative, high-demand drugs, investors often expect strong future earnings growth. A higher P/E ratio can sometimes reflect these expectations of strong future profits, especially for a company with exciting new products like their diabetes/obesity medicines.

When using the P/E ratio for Eli Lilly, you'd compare its current P/E to its historical P/E ratios and also to the P/E ratios of other large pharmaceutical companies. If Eli Lilly's P/E is much higher than its historical average or its peers, it might suggest the stock is expensive, implying investors have very high expectations for its future growth. If it's lower, it might suggest it's relatively cheaper, or that expectations are lower.